Epidural Steroid Injection — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

An epidural steroid injection (ESI) is an interventional pain management procedure in which a corticosteroid (such as triamcinolone acetonide, betamethasone, or methylprednisolone acetate) — combined with a local anaesthetic (bupivacaine or lidocaine) — is precisely delivered into the epidural space of the spinal column. The epidural space is the potential space between the dural sac (containing the spinal cord and nerve roots) and the surrounding vertebral bone and ligaments. When nerve roots are compressed or irritated by a herniated disc, spinal stenosis, or degenerative facet disease, an inflammatory cascade produces prostaglandins, cytokines, and substance P at the nerve root, generating radicular pain. The corticosteroid interrupts this inflammatory cascade, reducing oedema around the nerve root and decreasing nociceptive signalling along the affected nerve. ESIs are performed by interventional pain physicians, anaesthesiologists specialising in pain management, or spinal surgeons under real-time fluoroscopic (X-ray) or CT guidance in a sterile procedure room. They serve as a bridge between conservative management and surgery, allowing sufficient pain relief for effective physiotherapy participation or surgical decision-making based on symptom response. Approximately 9 million ESIs are performed annually in the United States.

ESIs are indicated for patients with radicular (nerve root) pain that has not adequately responded to 4–6 weeks of conservative management including physiotherapy, NSAIDs, and oral analgesics. Primary indications include: lumbar radiculopathy (sciatica) from L4–L5 or L5–S1 disc herniation causing buttock and leg pain in a dermatomal distribution; cervical radiculopathy from C5–C7 disc herniation or foraminal stenosis causing arm pain, paraesthesia, and weakness; neurogenic claudication from lumbar spinal stenosis causing bilateral leg pain and cramping aggravated by walking and relieved by sitting; and axial (non-radicular) back pain from inflammatory disc pathology or facet joint disease in selected cases. ESIs are particularly effective when MRI confirms disc herniation at the symptomatic level and the clinical symptoms and imaging are concordant. They are less effective in the absence of demonstrable structural pathology on MRI. ESIs provide a useful diagnostic tool — if targeted injection at the clinically suspected level relieves symptoms, this confirms the structural cause of pain and may help guide surgical planning. They are also used as temporising therapy for patients awaiting surgical listing.

ESIs are performed in a fluoroscopy suite with the patient prone (lying face down) or sitting. The skin over the injection site is cleaned with antiseptic and a small amount of local anaesthetic (lidocaine 1%) is infiltrated into the skin and subcutaneous tissues. Under real-time fluoroscopic imaging, the interventional needle (typically 22-gauge, 3.5 inch Quincke-tip) is advanced toward the target. Three approaches are used: transforaminal (selective nerve root block) — the needle is advanced into the neural foramen at the symptomatic level under oblique and lateral fluoroscopy, ideally depositing drug adjacent to the inflamed nerve root in the epidural fat; interlaminar — the needle enters the epidural space between adjacent laminae at the midline or paramedian, confirmed by loss-of-resistance technique with contrast; and caudal — the needle enters through the sacral hiatus for lower lumbar and sacral pathology. A small volume (0.5–1 ml) of iodinated contrast is first injected under live fluoroscopy to confirm epidural spread and exclude intravascular placement. The corticosteroid and local anaesthetic mixture (typically 3–5 ml total volume) is then injected. Fluoroscopy ensures accurate drug delivery and is now considered standard of care — blind injections without image guidance carry higher complication and malpositioning rates. The procedure takes 15–30 minutes in total.

ESIs achieve clinically meaningful short-term pain relief (>50% reduction on VAS or NRS) in 50–70% of patients with acute lumbar radiculopathy from disc herniation at 6–8 weeks after injection. They are more effective for acute disc-related radiculopathy than for chronic degenerative spinal stenosis (where response rates are lower, 30–50%). The primary benefit is not necessarily eliminating pain permanently, but achieving sufficient relief to allow effective participation in physiotherapy and restoration of function — critically reducing the need for surgical intervention. Multiple reviews show ESIs reduce the rate of subsequent surgery by 30–50% in patients with disc herniation and radiculopathy. Cervical transforaminal ESIs achieve 60–70% short-term improvement in cervical radiculopathy. Patient selection — those with acute or subacute radiculopathy, concordant MRI findings, and prior conservative management — maximises response rates. Combined ESI with structured physiotherapy produces better outcomes than either treatment alone, according to multiple randomised controlled trials.

ESIs are generally safe procedures, but complications range from minor and transient to serious and rare. Common minor side effects: post-injection pain flare (temporary worsening for 24–48 hours as the local anaesthetic wears off, affecting 5–10% of patients); facial flushing from corticosteroid (2–5 days); and insomnia in the first few nights. Dural puncture (wet tap) occurs in less than 1% of interlaminar injections, causing a post-dural puncture headache that is positional (worse upright, better lying flat) and typically resolves spontaneously in 5–7 days; persistent headaches are treated with a blood patch. Systemic steroid effects include transient hyperglycaemia in diabetics (blood glucose monitoring for 3–5 days post-injection is advised), adrenocortical suppression, and water retention — these are dose-dependent and generally transient. Infection (epidural abscess) is extremely rare (<0.001%) with sterile technique. Nerve root injury, spinal cord injury, and dural haematoma are very rare (<0.01%) serious complications; risk is minimised by fluoroscopic guidance, contrast confirmation of epidural spread, and strict patient selection (coagulopathy is a contraindication). ESIs are typically limited to 3 per spinal region per year to limit cumulative corticosteroid exposure.

Patients are observed for 30–60 minutes post-procedure before discharge. Driving is not permitted on the day of injection if sedation was administered; family member or taxi transport must be arranged. Rest for 24 hours is advised; patients avoid strenuous activity, hot baths, and swimming for 48 hours. A temporary increase in pain (post-injection flare) may occur for 24–48 hours as the local anaesthetic wears off before the corticosteroid anti-inflammatory effect begins. Ice packs applied to the injection site for 20 minutes at a time may reduce this. The corticosteroid effect develops over 3–7 days, with maximum benefit typically experienced at 2 weeks. Patients should use a pain diary to track response, and physiotherapy appointments should be coordinated to begin within 1–2 weeks post-injection while relief is maximal. If significant relief is achieved, physiotherapy should be intensified to make lasting functional improvements. If a first injection provides only partial or temporary relief, a second injection may be performed at 6 weeks. Most guidelines recommend a maximum of 3 injections per region per year. Lack of any response after 2 injections is a strong indicator that this treatment modality will not be effective for this patient.